Vor Biopharma Inc. (VOR) News
Follow Vor Biopharma Inc. (VOR) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 14 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Form SCHEDULE 13G/A Vor Biopharma Inc. Filed by: FMR LLC
Filed on: November 5, 20
EQUITY | Nov 05, 2026, 06:27 PM UTC
M
VOR Reports Fiscal Q3 Net Loss
VOR reported a fiscal 2026 third-quarter net loss attributable to shareholders, up 84.74% year over year. Basic earnings per share were negative.
EQUITY | Nov 02, 2026, 10:21 AM UTC
L
Vor Bio Reports 48-Week gMG Data: 42% Reached MSE
Vor Bio reported post hoc 48-week data from a China Phase 3 gMG study of telitacicept: 42% reached minimal symptom expression at any time; >94% had ≥5-point MG-ADL improvement. Most MSE events were sustained at the next
GEOPOLITICS | Sep 29, 2026, 12:09 PM UTC
L
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
More than 94% of participants achieved a ≥5-point MG-ADL improvement at Week 4842% of telitacicept-treated participants achieved minimal symptom expression (MSE) at any time over 48 weeks, increasing from 23.7% over the
NEWS | Sep 29, 2026, 12:09 PM UTC
M
VOR advances Phase III Telitacicept trials for myasthenia gravis, Sjögren’s
VOR says Telitacicept, a BAFF-APRIL inhibitor, is advancing in Phase III trials for myasthenia gravis and Sjögren’s, citing strong early enrollment and a differentiated B-cell targeting mechanism. Top-line MG data is ant
EQUITY | Sep 09, 2026, 05:06 PM UTC
L
VOR trial update highlights late-stage progress for Telitacicept
Telitacicept is advancing in late-stage trials for myasthenia gravis and Sjögren's disease, with differentiation tied to its dual BAFF-APRIL mechanism and robust safety data from China.
GEOPOLITICS | Sep 09, 2026, 04:30 PM UTC
M
VOR completes Phase III MG trial enrollment; global readout set for 2027
VOR says Phase III MG trial enrollment is completed. A key global readout is expected in 2027, alongside plans for an ocular MG study, with management citing China data on efficacy and durability.
GEOPOLITICS | Sep 08, 2026, 02:01 PM UTC
M
VOR Phase III MG enrollment complete; key readout eyed for early 2027
VOR says enrollment in its Phase III MG trial is complete, with a key readout expected in early 2027. The company also plans an ocular MG study and enhanced dosing convenience.
EQUITY | Sep 08, 2026, 01:27 PM UTC
M
VOR completes Phase III telitacicept enrollment; key readout set for early 2027
VOR says enrollment is complete for its Phase III telitacicept MG trial, with a key readout expected in early 2027. The company is expanding into ocular MG and Sjögren’s, highlighting a dual BAFF/APRIL mechanism.
EQUITY | Sep 08, 2026, 01:10 PM UTC
M
VOR completes Phase 3 UPSTREAM MG enrollment, expands telitacicept to ocular MG
VOR says it completed enrollment in its global Phase 3 UPSTREAM MG trial and expanded its telitacicept global franchise into ocular myasthenia gravis.
EQUITY | Sep 08, 2026, 11:00 AM UTC
L
Vor Bio reports inducement grant under Nasdaq Rule 5635(c)(4)
Vor Bio reports an inducement grant under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 04, 2026, 08:05 PM UTC
L
VOR - Vor Bio To Participate in Upcoming September Conferences
VOR - Vor Bio To Participate in Upcoming September Conferences
EQUITY | Sep 01, 2026, 12:02 PM UTC
L
Vor Biopharma Q2 Adj. EPS Misses Estimate
Vor Biopharma reports Q2 adjusted EPS of $(0.80), missing the $(0.70) estimate
EARNINGS | Aug 11, 2026, 09:30 PM UTC
L
Vor Bio Reports Inducement Grant
Vor Bio grants inducement award
EQUITY | Aug 03, 2026, 08:30 PM UTC